GlassScriptPhysician profile
Dasrine K Gordon
NPI 1295235943
$6,578.87
in general payments reported to CMS, 2019-2025
27 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $837 · 2023: $1,301 · 2024: $2,675 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,070.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,229.56 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,137.82 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,106.69 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $1,057.21 | 2021-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $522.88 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $192.95 | 2021-2024 | |
| Lilly USA, LLC | $158.97 | 2021-2023 | Mounjaro, Jardiance |
| Abbott Laboratories | $157.72 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Ibsa Pharma INC. | $125.00 | 2024 | Tirosint |
| Sobi, INC | $125.00 | 2023 | |
| Pharming Healthcare, INC. | $124.99 | 2024 | Ruconest |
| Alkermes, INC. | $100.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $69.85 | 2024 | |
| Pfizer INC. | $62.22 | 2023-2024 | |
| Amarin Pharma, INC. | $57.75 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.66 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.19 | 2021-2023 | Jardiance |
| Exact Sciences Corporation | $36.44 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $35.13 | 2024 | Rexulti |
| Lucid Diagnostics INC. | $34.34 | 2024 | |
| Shield Therapeutics INC | $33.34 | 2023-2024 | Accrufer |
| Radius Health, INC. | $31.99 | 2024 | |
| Scilex Pharmaceuticals INC. | $18.40 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.90 | 2024 | Unithroid |
| Medtronic, INC. | $15.63 | 2024 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $14.81 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $14.43 | 2023 | Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dasrine Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.